Spying on the virus: Development to increase effectiveness of viral cancer therapy

September 10, 2018, National University of Science and Technology MISIS
Intravital microscope. Credit: © Pavel Melnikov, Pirogov Russian National Research Medical University (RNRMU)

Scientists have learned how to observe the processes of oncolytic viruses in cancer cells in real time. For the first time ever, a group of scientists from NUST MISIS and the University of Calgary (Canada) has applied intravital microscopy to study the interaction of oncolytic viruses with both tumor cells and healthy cells. With the technology, researchers can visualize how the virus behaves in the tissues of a living organism. The research results have been published in international scientific journal Molecular Therapy Oncolytics.

Today, doctors typically treat cancer via radiation or chemotherapy. Therapy with an oncolytic virus—virotherapy or oncolytics—is a fairly new and promising method of cancer treatment based on the genetic engineering of special modified viruses that target and kill . Oncolytic viruses also stimulate anticancer immunity, which leads the tumor to destroy itself.

The immune system must destroy cancer cells immediately to prevent damage, but cancer cells have special biochemical tricks that allow them to bypass the immune system. That is why cancer sometimes doesn't appear until it's at a critical stage.

On the other hand, antiviral protection doesn't work well in due to a defect in the interferon system. As a result, oncolytic viruses can contribute to the death of malignant cells, and "attract the attention" of the immune system so that it finally detects the remaining cancer. The cancer cell, affected by the virus, releases signals to the immune system. Recognizing the tumor, the immune system directs killer T cells to fight it.

The arrows indicate examples of white blood cells connected with many viral particles, forming a «halo» around the cell surface. Credit: © NUST MISIS

Although this method is being studied in the U.S., Europe and China, it hasn't yet received mass application. This is largely due to a lack of understanding how these work. For the first time ever, an international team of scientists led by Victor Naumenko, a candidate of medical sciences and a researcher at the NUST MISIS Biomedical Nanomaterials Laboratory, has applied the modern method of intravital microscopy to study the delivery of the virus to a tumor to monitor the dynamics of the virus's spread and to simulate the immune system.

"We have developed a technique that allows us to monitor the virus in a living organism. We have conducted our experiments on the vesicular stomatitis virus, which is completely safe for humans, [as well as being] easy to genetically modify and easy to produce in large quantities. At the same time, most tumor lines are sensitive to this virus. The can be marked with dyes that preserve its biological activity and provide visualization in animal tissues through single- and two-photon microscopy," said Victor Naumenko.

Microscopy of monocytes, capturing the virus (in blue) in tumor vessels. The arrow points to several localized virus particles on the cell surface. Credit: © NUST MISIS

Modern microscopic research is mostly about studies of dead tissues and cell samples. However, the intravital microscope allows researchers to observe the processes in living tissues and organs in real time, while the examined animal is under anesthesia, and the high resolution allows them to see individual cells and track their interactions.

Researchers have managed to visualize the dynamic interactions between the virus and the body's cells in the blood, tumors, and internal organs of living mice in an "online" mode.

"The method has a sufficient resolution to monitor the in vivo capture and transfer of viral particles by leukocytes, the spread of the infection site in tumors, and the activation of immune processes in the spleen and lymph nodes. We believe that this technology is a powerful new tool for studying and optimizating virotherapy," Naumenko declared.

Explore further: Clinical trial uses a genetically engineered virus to fight cancer

More information: Victor Naumenko et al, Visualizing Oncolytic Virus-Host Interactions in Live Mice Using Intravital Microscopy, Molecular Therapy - Oncolytics (2018). DOI: 10.1016/j.omto.2018.06.001

Related Stories

Clinical trial uses a genetically engineered virus to fight cancer

August 15, 2017
Sanford Health is the first site in the United States to launch a clinical trial using a genetically-engineered virus that aims to destroy therapy-resistant tumors.

Adenoviruses and the immune system join forces against cancer

February 16, 2017
Researchers of the Cancer Virotherapy Research Group of Bellvitge Biomedicine Research Institute (IDIBELL), led by Dr. Ramon Alemany, have developed an oncolytic virus capable of redirecting the patient's immune system against ...

VCP protein inhibitor found to help virus kill liver tumors

August 24, 2017
(Medical Xpress)—A team of researchers with members from several institutions in China has found that combining a VCP protein inhibitor with a virus that naturally targets liver cancer tumors made the virus much more potent. ...

Discovery means individualized ovarian, brain cancer therapies

May 16, 2018
Mayo Clinic researchers have discovered that a molecular communication pathway—thought to be defective in cancer—is a key player in determining the effectiveness of measles virus oncolytic cancer treatment in ovarian ...

Fully reprogrammed virus offers new hope as cancer treatment

May 25, 2018
A cancer treatment that can completely destroy cancer cells without affecting healthy cells could soon be a possibility, thanks to research led by Cardiff University.

Size matters when fighting cancer, study finds

April 27, 2018
Doctors could be a step closer to finding the most effective way to treat cancer with a double whammy of a virus combined with boosting the natural immune system, according to a pioneering study by researchers at The University ...

Recommended for you

Eating foods with low nutritional quality ratings linked to cancer risk in large European cohort

September 18, 2018
The consumption of foods with higher scores on the British Food Standards Agency nutrient profiling system (FSAm-NPS), reflecting a lower nutritional quality, is associated with an increased risk of developing cancer, according ...

CRISPR screen reveals new targets in more than half of all squamous cell carcinomas

September 18, 2018
A little p63 goes a long way in embryonic development—and flaws in p63 can result in birth defects like cleft palette, fused fingers or even missing limbs. But once this early work is done, p63 goes silent, sitting quietly ...

Could the zika virus fight the brain cancer that killed john McCain?

September 18, 2018
(HealthDay)—Preliminary research in mice suggests that the Zika virus might be turned from foe into friend—enlisted to curb deadly glioblastoma brain tumors.

Enlarged genotype-phenotype correlation for a three-base pair deletion in neurofibromatosis type 1

September 18, 2018
International collaborative research led by Ludwine Messiaen, Ph.D., shows that while a three-base pair, in-frame deletion called p.Met992del in the NF1 gene has a mild phenotype for people with the genetic disorder neurofibromatosis ...

Your teen is underestimating the health risks of vaping

September 17, 2018
Teens today are more reluctant to smoke cigarettes than their counterparts nearly three decades ago, according to a study released this summer. But parents should hold their collective sigh of relief. The study, carried out ...

Artificial intelligence can determine lung cancer type

September 17, 2018
A new computer program can analyze images of patients' lung tumors, specify cancer types, and even identify altered genes driving abnormal cell growth, a new study shows.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.